Elevated serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) in patients with nonalcoholic steatohepatitis and chronic hepatitis C.

Yilmaz Y., Dolar E., Ulukaya E., Akgoz S., Keskin M., KIYICI M., ...More

Medical science monitor : international medical journal of experimental and clinical research, vol.15, no.4, 2009 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 15 Issue: 4
  • Publication Date: 2009
  • Journal Name: Medical science monitor : international medical journal of experimental and clinical research
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Keywords: nonalcoholic steatohepatitis, chronic hepatitis C, apoptosis, histopathology, biomarker, FATTY LIVER-DISEASE, EXTRACELLULAR CYTOKERATIN-18, SCORING SYSTEM, SOLUBLE FORMS, APOPTOSIS, EXPRESSION, STEATOSIS
  • Bursa Uludag University Affiliated: Yes

Abstract

Background: Caspase-cleaved cytokeratin 18 (CK18-Asp396) is released from hepatocytes during apoptosis. Recent studies have indicated that serum levels of CK18-Asp396 could be clinically useful biomarker of chronic liver disease. To shed more light on the rate of hepatocyte loss by apoptosis in chronic liver disease, serum levels of CK18-Asp396 were examined in patients with nonalcoholic steatohepatitis (NASH) and chronic hepatitis C.